TB and COVID-19 – a dangerous new combination? Source: ERS webinar 2021: TB and COVID-19 – a dangerous new combination? Year: 2021
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Delay in sputum conversion of patients with treated tuberculosis; how could it be considered? Source: Eur Respir J 2007; 30: Suppl. 51, 87s Year: 2007
The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012
What happens when an oral tuberculosis is not treated? Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007
Treatment results and follow up of patients with chronic multidrug resistant tuberculosis Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
M. tuberculosis W-strain: MDR or no?Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
The use of phon resonant therapy (PRT) in treatment of patients with pulmonary tuberculosis, combined with infections, caused by chlamydia (C) and mycoplasma (M) Source: Eur Respir J 2004; 24: Suppl. 48, 52s Year: 2004
When, where, and how to treat tuberculosis in multiple drug resistant patients Source: International Congress 2016 – PG10 Tuberculosis management: a personalised clinical approach Year: 2016
Treatment of MDR tuberculosis in Switzerland. A case control study Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
In vitro and in vivo activity of thiourea (ISO), a mycolic acid inhibitor, against multi drug resistant (MDR) strains of Mycobacterium tuberculosis (M. tb )Source: Eur Respir J 2005; 26: Suppl. 49, 700s Year: 2005
Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002
The efficiency of the treatment of the patients with culture-positive pulmonary tuberculosis (CPPTB) in Gdannsk, Poland in 1995 and 2000 Source: Annual Congress 2005 - Epidemiology and control of tuberculosis and LTBI Year: 2005
Can M. smegmatis be used as a real alternative for M. tuberculosis? Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR Year: 2016
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
Pulmonary tuberculosis control: does COVID-19 have any effect? Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021
Multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) : global response Source: International Congress 2017 – Update on TB: latest news Year: 2017
Treatment of pulmonary NTM infection: can it be done? Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006